• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease.

作者信息

Towerman Alison S, Guilliams Kristin P, Guerriero Réjean, Shinawi Marwan S, Stoll Janis M, Willis Daniel N, Hulbert Monica L

机构信息

Division of Hematology/Oncology, Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

Trudy Busch Valentine School of Nursing, Saint Louis University, St. Louis, Missouri, USA.

出版信息

Br J Haematol. 2023 May;201(4):e30-e33. doi: 10.1111/bjh.18770. Epub 2023 Mar 25.

DOI:10.1111/bjh.18770
PMID:36964994
Abstract
摘要

相似文献

1
Hyperammonemia and acute liver failure associated with deferasirox in two adolescents with sickle cell disease.两名镰状细胞病青少年使用地拉罗司后出现高氨血症和急性肝衰竭。
Br J Haematol. 2023 May;201(4):e30-e33. doi: 10.1111/bjh.18770. Epub 2023 Mar 25.
2
Acute hyperammonemia in children under deferasirox treatment: cutting the Gordian knot.接受地拉罗司治疗的儿童急性高氨血症：快刀斩乱麻。
Clin Toxicol (Phila). 2019 May;57(5):375-377. doi: 10.1080/15563650.2018.1523425. Epub 2018 Nov 16.
3
Acute Liver Failure During Deferasirox Chelation: A Toxicity Worth Considering.去铁胺螯合治疗期间的急性肝衰竭：一种值得关注的毒性反应。
J Pediatr Hematol Oncol. 2017 Apr;39(3):217-222. doi: 10.1097/MPH.0000000000000786.
4
Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.两年疗效和安全性分析：去铁酮治疗镰状细胞贫血患者输血铁过载。
Acta Haematol. 2012;128(2):113-8. doi: 10.1159/000338560. Epub 2012 Jun 30.
5
Reversible retinopathy associated with oral deferasirox therapy.与口服地拉罗司治疗相关的可逆性视网膜病变。
BMJ Case Rep. 2013 Jul 17;2013:bcr2013009205. doi: 10.1136/bcr-2013-009205.
6
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.地拉罗司与去铁胺治疗镰状细胞病输血性铁过载的随机对照研究
Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x.
7
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.比较去铁酮与去铁胺在镰状细胞病中的疗效和安全性：包括药代动力学和同时使用羟基脲的两年结果。
Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.
8
Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).去铁酮在依赖输血的地中海贫血或镰状细胞贫血儿童中的应用：来自土耳其的大型队列真实世界经验（REACH-THEM）。
Eur J Haematol. 2019 Feb;102(2):123-130. doi: 10.1111/ejh.13180. Epub 2018 Dec 9.
9
Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients.去铁胺对镰状细胞病患者进行4年治疗的安全性和有效性
Hemoglobin. 2013;37(1):94-100. doi: 10.3109/03630269.2012.746696. Epub 2012 Dec 7.
10
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.地拉罗司可有效降低双重杂合子 HbS/β-地中海贫血患者的铁负荷。
Ann Hematol. 2011 Jan;90(1):11-5. doi: 10.1007/s00277-010-1029-7. Epub 2010 Jul 27.

引用本文的文献

1
Extracorporeal Blood Purification Therapy to Deal a Deferasirox Induced Life-Threatening Hepatic Encephalopathy in a Septic Child With Sickle-Cell Disease: A Case Report.体外血液净化疗法治疗镰状细胞病败血症患儿中地拉罗司诱发的危及生命的肝性脑病：一例报告
J Clin Apher. 2025 Jun;40(3):e70032. doi: 10.1002/jca.70032.
2
Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.铁霉素通过靶向铁代谢成瘾诱导套细胞淋巴瘤细胞死亡。
Theranostics. 2025 Feb 3;15(7):2834-2851. doi: 10.7150/thno.101821. eCollection 2025.
3
Drug-induced liver injury from Deferasirox in a pediatric patient with hereditary spherocytosis: A case report.
一名遗传性球形红细胞增多症儿科患者使用地拉罗司后发生药物性肝损伤：病例报告
JPGN Rep. 2024 Dec 16;6(1):56-59. doi: 10.1002/jpr3.12155. eCollection 2025 Feb.
4
Quo vadis ureagenesis disorders? A journey from 90 years ago into the future.尿素生成障碍疾病将去往何方？从 90 年前追溯到未来。
J Inherit Metab Dis. 2024 Nov;47(6):1120-1128. doi: 10.1002/jimd.12763. Epub 2024 Jun 4.